Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

749
Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
749
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

516
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
516

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Tumour deposits in colorectal carcinoma are associated with immune evasion and dose-dependent adverse prognosis beyond nodal status.

British journal of cancer·2026
Same author

Indirect Treatment Comparison of Riociguat Replacement Therapy and Selexipag Add-on Therapy in Patients With Pulmonary Arterial Hypertension: Results From a Systematic Review.

Reviews in cardiovascular medicine·2026
Same author

Extra-appendiceal low-grade mucinous neoplasm-like lesions: clinicopathologic and molecular characteristics.

Histopathology·2026
Same author

Discovery of a KLHL41 Ligand for Muscle Specific Protein Degradation.

Nature communications·2026
Same author

What affects natural killer cell activity: a cross-sectional study.

Frontiers in immunology·2026
Same author

RPS6KA3/RSK2-mediated phosphorylation of DRAM2 promotes lysosomal targeting and autophagic flux in melanoma.

Autophagy·2026

Related Experiment Video

Updated: Jan 7, 2026

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies
07:20

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies

Published on: January 28, 2014

37.1K

Biomarkers.

Hana Cho1, Kyoung-Ryul Lee1, Seongeun Jeong1

  • 1Korea Institute of Science and Technology, Seoul, Korea, Republic of (South).

Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association
|December 26, 2025
PubMed
Summary

Glial fibrillary acidic protein (GFAP) and phosphorylated tau (p-tau) blood biomarkers show promise for Alzheimer's disease (AD) diagnosis. Combining GFAP and p-tau improves diagnostic accuracy compared to single biomarkers, aiding in AD prognosis.

More Related Videos

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
07:35

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

7.9K
Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans
08:14

Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans

Published on: April 28, 2023

702

Related Experiment Videos

Last Updated: Jan 7, 2026

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies
07:20

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies

Published on: January 28, 2014

37.1K
Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
07:35

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

7.9K
Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans
08:14

Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans

Published on: April 28, 2023

702

Area of Science:

  • Neuroscience
  • Biochemistry
  • Medical Diagnostics

Background:

  • Alzheimer's disease (AD) diagnosis relies on biomarkers like amyloid-beta and phosphorylated tau (p-tau).
  • Glial fibrillary acidic protein (GFAP) shows potential in reflecting and predicting disability in neurodegenerative diseases.
  • Exploring novel biomarkers like GFAP is crucial for validating pathological mechanisms and improving clinical data reliability in AD.

Purpose of the Study:

  • To measure glial fibrillary acidic protein (GFAP) and phosphorylated tau (p-tau) levels in human blood.
  • To evaluate the correlation between GFAP and p-tau levels for Alzheimer's disease (AD) diagnosis.
  • To assess the diagnostic potential of these biomarkers using a magnetic bead-based electrochemical sensor.

Main Methods:

  • Magnetic beads coated with specific antibodies were used for GFAP and p-tau detection.
  • Blood samples from normal controls (NC), mild cognitive impairment (MCI), and AD patients were analyzed.
  • Impedance change rates of GFAP and p-tau were compared to differentiate between NC, MCI, and AD groups.

Main Results:

  • Both GFAP and p-tau showed low impedance change rates in normal controls.
  • MCI patients exhibited slightly elevated impedance change rates compared to controls.
  • AD patients displayed the highest impedance change rates, approximately double that of controls, indicating significant astrocyte activation.
  • Multi-biomarker analysis demonstrated superior diagnostic reliability (higher Area Under Curve values) compared to single biomarkers.

Conclusions:

  • GFAP and p-tau blood levels, measured via a magnetic bead-based electrochemical sensor, correlate with Alzheimer's disease (AD) status.
  • GFAP effectively indicates astrocyte activation in individuals across the NC, MCI, and AD spectrum.
  • Combining GFAP and p-tau enhances diagnostic accuracy for AD, suggesting potential for improved prognosis and point-of-care applications.